BridgeBio Pharma (BBIO) FCF Payout Ratio (2019)
BridgeBio Pharma's (BBIO) quarterly FCF Payout Ratio came in at 1.07 in Q3 2019, down 6305.97% quarter-over-quarter from 0.02 in Q1 2019.
BridgeBio Pharma (BBIO) FCF Payout Ratio (2019) Analysis & Trends
BridgeBio Pharma has disclosed FCF Payout Ratio across 1 years of filings, most recently posting 1.07 for Q3 2019.
- FCF Payout Ratio for Q3 2019 came in at 1.07, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was 0.21 (changed N/A YoY), and the FY2020 annual result was 0.01, up 94.19% from the prior year.
- FCF Payout Ratio came in at 1.07 for Q3 2019 at BridgeBio Pharma, down from 0.02 in the prior quarter.
- In the past five years, FCF Payout Ratio ranged from a high of 0.02 in Q1 2019 to a low of 1.07 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BridgeBio Pharma | 12.90 Bn | 11.97 Bn | 184.58 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -1.07 |
| Mar 31, 2019 | -0.02 |